JPRN-UMIN000050556招募中Unknown
The Efficacy and Safety of Imeglimine in Elderly People with Type 2 Diabetes Mellitus - Imeglimin in Elderly Diabetes
Kitasato University School of Medicine0 个研究点目标入组 50 人开始时间: 2023年3月11日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients on multiple insulin injection therapy (basal and bolus insulin therapy) 2) Patients with renal dysfunction (glomerular filtration rate (eGFR) <45 mL/min/1.73 m2) 3) Patients with severe anemia (Hb < 10g/dL) 4) Patients who are using an implantable medical device (e.g. pacemaker) 5) Patients with severe cognitive impairment 6) Patients with active malignant tumors 7) Patients who are judged by the principal investigator or subinvestigator to be inappropriate to participate in this clinical research
研究者
相似试验
尚未招募
4 期
Study of efficacy and side effects of imeglimin as an antidiabetic agent as single drug or as an add on drugCTRI/2024/04/065835Abhinav Garg
进行中（未招募）
不适用
EFFICACY AND SAFETY OF OLMESARTAN IN ELDERLY PATIENTS WITH MILD TO MODERATE HYPERTENSIOEUCTR2004-001616-31-ITSOFARMACO
招募中
不适用
Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutationsnon-small-cell lung cancerJPRN-UMIN000012056Shimane university hospital38
已完成
不适用
Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer without epidermal growth factor receptor mutations: A phase 2 trial.JPRN-UMIN000010526Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine42
已完成
不适用
Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutations: A phase 2 study.non-small-cell lung cancerJPRN-UMIN000010525Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine30